异质性缺失数据模式在前列腺癌风险预测中的应用
Accommodating heterogeneous missing data patterns for prostate cancer risk prediction
摘要:
目的:我们比较了六种常用的逻辑斯谛回归方法,以适应来自多个异质队列的缺失风险因素数据,其中一些队列根本不收集一些风险因素,并开发了一种在线风险预测工具,以适应来自最终用户的缺失风险因素。研究设计和环境:来自前列腺活检协作组(PBCG)的10个北美和欧洲队列用于拟合临床显著前列腺癌的风险预测工具,定义为标准TRUS前列腺活检的Gleason分级组大于或等于2。一个大型欧洲PBCG队列被保留用于外部验证,其中评价了大样本校准(CIL)、校准曲线和受试者工作特征曲线下面积(AUC)。十重留一队列内部验证进一步验证了最佳缺失数据方法。结果如下:在来自10个培训队列的12,703例活检中,3,597例(28%)患有临床显著的前列腺癌,而外部验证队列中的5,540例中有1,757例(32%)。在外部验证中,汇总包含最终用户输入的所有风险因素的个体患者数据的可用病例方法具有最佳CIL,平均低估风险百分比2.9%,并获得75.7%的AUC。插补的CIL最差(-13.3%)。在内部交叉验证中进一步验证了可用案例方法的最佳性,并将其用于开发在线风险工具。对于风险工具的最终用户,两个风险因素是强制性的:血清前列腺特异性抗原(PSA)和年龄,10个是可选的:直肠指检,前列腺体积,既往阴性活检,5-α-还原酶抑制剂的使用,既往PSA筛查,非洲血统,西班牙裔种族,一级前列腺癌,乳腺癌和二级前列腺癌家族史。
英文摘要:
Objective: We compared six commonly used logistic regression methods for accommodating missing risk factor data from multiple heterogeneous cohorts, in which some cohorts do not collect some risk factors at all, and developed an online risk prediction tool that accommodates missing risk factors from the end-user. Study Design and Setting: Ten North American and European cohorts from the Prostate Biopsy Collaborative Group (PBCG) were used for fitting a risk prediction tool for clinically significant prostate cancer, defined as Gleason grade group greater or equal 2 on standard TRUS prostate biopsy. One large European PBCG cohort was withheld for external validation, where calibration-in-the-large (CIL), calibration curves, and area-underneath-the-receiver-operating characteristic curve (AUC) were evaluated. Ten-fold leave-one-cohort-internal validation further validated the optimal missing data approach. Results: Among 12,703 biopsies from 10 training cohorts, 3,597 (28%) had clinically significant prostate cancer, compared to 1,757 of 5,540 (32%) in the external validation cohort. In external validation, the available cases method that pooled individual patient data containing all risk factors input by an end-user had best CIL, under-predicting risks as percentages by 2.9% on average, and obtained an AUC of 75.7%. Imputation had the worst CIL (-13.3%). The available cases method was further validated as optimal in internal cross-validation and thus used for development of an online risk tool. For end-users of the risk tool, two risk factors were mandatory: serum prostate-specific antigen (PSA) and age, and ten were optional: digital rectal exam, prostate volume, prior negative biopsy, 5-alpha-reductase-inhibitor use, prior PSA screen, African ancestry, Hispanic ethnicity, first-degree prostate-, breast-, and second-degree prostate-cancer family history.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。